logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Cancer and Palliative Care

Results

Drugs

August 2021

Sabatolimab in addition to azacitidine for myelodysplastic syndromes – first-line

Sabatolimab in addition to azacitidine is in clinical development for the treatment of higher risk myelodysplastic syndromes (MDS) in adults. Myelodysplastic syndromes are a group of cancers in which immature blood cells in the bone marrow do not mature or become healthy blood cells. MDS are long-term debilitating and life-threatening diseases Sabatolimab targets an inhibitory …

Drugs

August 2021

Pembrolizumab for Hepatocellular Carcinoma – Adjuvant

Pembrolizumab is in clinical development as an adjuvant treatment for hepatocellular carcinoma (HCC). HCC is the most common type of liver cancer. This type of cancer develops from the main liver cells, called hepatocytes. Treatment and survival depends on the stage at which the cancer is diagnosed. HCC is more common in people who have …

Drugs

August 2021

Pembrolizumab in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for early-strage breast cancer

Pembrolizumab in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy is in clinical development for the treatment of early-stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) breast cancer. Early breast cancer is where the disease is limited to the breast region and has not spread to other parts of the body. Treatment of …

Drugs

August 2021

Infigratinib for unresectable locally advanced or metastatic cholangiocarinoma with FGFR2 rearrangements – second line

Cholangiocarcinoma (CCA) is a rare type of cancer that affects the bile ducts. Locally advanced CCA is when the cancer spreads from its original site to surround areas, but has not spread to other parts of the body. Metastatic CCA is when the cancer has spread to other areas of the body. Current treatment options …

Drugs

August 2021

Mobocertinib for locally advanced or metastatic NSCLC

Mobocertinib (TAK-788) as a monotherapy is in clinical developmentfor the treatment oflocallyadvanced or metastatic non-small cell lung cancer (NSCLC). NSCLC makes up the majority of lung cancers in the UK. In locally advanced or metastaticNSCLC(StageIIIB orIV),the cancer has spread beyond the lung which was initially affected. Symptoms of lung cancer include a persistent cough, shortness …

Drugs

August 2021

Amivantamab for advanced non-small-cell lung cancer

Amivantamab is in clinical development in the treatment of patients with advanced non-small-cell lung cancer (NSCLC) who have previously been treated with platnum-based chemotherapy. NSCLC makes up the majority of lung cancers in the UK. Metastatic NSCLC is when the cancer has spread beyond the lung that was initially affected, most often to the liver, …

Drugs

July 2021

Afamitresgene autoleucel for advanced synovial sarcoma or myxoid/round cell liposarcoma

Afamitresgene autoleucel is in clinical development for the treatment of advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) in patients who have previously had chemotherapy. Both synovial sarcoma and MRCLS are two different types of soft tissue sarcomas (STS), a rare form of cancer that develops in the tissues that connect, support and surround other …

Drugs

July 2021

Pembrolizumab in combination with lenvatinib, platinum chemotherapy, and pemetrexed for non-small cell lung cancer

The combination of pembrolizumab, lenvatinib, platinum chemotherapy, and pemetrexed is in clinical development for the treatment of metastatic non-squamous non-small cell lung cancer (NSCLC). NSCLC makes up the majority of lung cancers in the UK and at the metastatic stage (stage IV), the disease has already spread from the lungs to other sites. Most patients …

Drugs

July 2021

Nivolumab in combination with ipilimumab for gastric or gastroesophageal junction cancer – first line

Nivolumab in combination with ipilimumab is under development for the treatment of advanced gastric or gastroesophageal junction cancer. Gastric cancer is a malignant tumour originating in the cells of the stomach. Advanced gastric cancer begins in the stomach and spread into the tissues around the stomach, either as locally advanced disease, or it can metastasise …

Drugs

June 2021

Duvelisib for Relapsed or Refractory Chronic Lymphocytic Leukaemia

Duvelisib is an anti-cancer drug in clinical development for adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) after at least two prior therapies. CLL is a type of cancer in which too many white blood cells are produced. As these cells develop abnormally, they are unable to function and fight infection and reduce …

Get Alerts